Page 1

❤DocMorris Frauenfeld , 15 October 2026 Press release Ad hoc announcement pursuant to Art . 53 LR DocMorris accelerates Rx growth to 78 % in Q3 ; EBITDA breakeven already achieved in Q3 and revenue and EBITDA forecast for 2026 raised again Revenue growth of 21.5 % in Q3 and 15.5 % in the first nine months Strong acceleration of Rx growth to 78.3 % versus Q3 2025 ; plus 33.5 % versus Q2 2026 Non - Rx up 5.5 % in Q3 , of which Digital Services up 46.1 % Adjusted EBITDA of CHF 0.6 million in Q3 Revenue and adjusted EBITDA guidance for 2026 increased CEO Walter Hess says : “ Our revenue growth accelerated again in the third quarter of 2026 , demonstrating that our offering is well received by patients . We will continue to consistently leverage this Rx momentum to expand our customer base and further solidify our position in the digital healthcare market . " CFO Daniel Wüest adds : “ Thanks to the strong performance of Rx and Digital Services , as well as further improvements in cost and marketing efficiency , we already achieved our targeted EBITDA breakeven in the third quarter with adjusted EBITDA of CHF 0.6 million . Against this backdrop , we are once again raising our revenue and EBITDA guidance for the full year . " Significantly accelerated Rx growth in the third quarter DocMorris increased its external revenue¹ in the third quarter of 2026 significantly by 21.5 per cent² year - on - year to CHF 342.7 million , while revenue increased by 22.2 per cent to CHF 327.4 million . In the segment Germany , external revenue increased by 22.0 per cent . External revenue growth for prescription medicines ( Rx ) accelerated in the third quarter to 78.3 per cent year - on - year ; Rx external revenue was 33.5 per cent higher than in the already strong second quarter of 2026 ( up 17.0 per cent in Q2 compared to Q1 2026 ) . Non - Rx³ external revenue increased by 5.5 per cent . The OTC business grew as planned by 3.5 per cent . Digital Services , comprising TeleClinic , Retail Media and Marketplace , achieved revenue growth of 46.1 per cent to CHF 13.9 million , with a further increase in earnings contribution . In the segment Europe , revenue increased by 12.0 per cent . 1 External revenue consists of the revenue of DocMorris plus online revenue of apotal , less revenue related to supplies to apotal . 2 All percentages are in local currency . 3 Consisting of OTC business and Digital Services ( TeleClinic , Retail Media , Marketplace ) . DocMorris AG Walzmühlestrasse 49 8500 Frauenfeld Switzerland corporate.docmorris.com